Andrew Cheng
CIK 1778307 · President and CEO · last filed 2026-05-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$599.1K
Companies
3
Total Filings
82
Lifetime Open-Market Net
-$43.39M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 6 of 9
82 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-01-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.27M | EDGAR |
| 2022-12-20 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | +8,500 | $5.2K | EDGAR |
| 2022-12-13 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +52,351 | $0 | EDGAR |
| 2022-12-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$454.6K | EDGAR |
| 2022-11-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$428.0K | EDGAR |
| 2022-10-05 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$326.1K | EDGAR |
| 2022-09-15 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.61M | EDGAR |
| 2022-09-13 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +1,152 | $9.3K | EDGAR |
| 2022-05-26 | VERA | Grant (A) | — | $0 | EDGAR |
| 2022-03-02 | Akero Therapeutics, Inc. (AKRO) Delisted | — | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.